{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:25:15Z","timestamp":1780539915879,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,11,16]],"date-time":"2010-11-16T00:00:00Z","timestamp":1289865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11899-010-0068-4","type":"journal-article","created":{"date-parts":[[2010,11,15]],"date-time":"2010-11-15T12:47:17Z","timestamp":1289825237000},"page":"22-27","source":"Crossref","is-referenced-by-count":5,"title":["Future Therapies for the Myeloproliferative Neoplasms"],"prefix":"10.1007","volume":"6","author":[{"given":"Robyn","family":"Scherber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,11,16]]},"reference":[{"issue":"5","key":"68_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"\u2022 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al.: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937\u201351. This key reference addresses the WHO changes in the diagnosis of the MPNs, addressing the neoplastic nature of the illnesses and the current diagnostic criteria.","journal-title":"Blood"},{"issue":"6","key":"68_CR2","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.leukres.2006.12.002","volume":"31","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Verstovsek S, Cervantes F, et al.: Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007, 31(6):737\u201340.","journal-title":"Leuk Res"},{"issue":"2","key":"68_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MOH.0b013e3282f3debd","volume":"15","author":"RA Mesa","year":"2008","unstructured":"Mesa RA. New insights into the pathogenesis and treatment of chronic myeloproliferative disorders. Curr Opin Hematol 2008, 15(2):121\u20136.","journal-title":"Curr Opin Hematol"},{"issue":"13","key":"68_CR4","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"\u2022 Cervantes F, Dupriez B, Pereira A, et al.: New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009, 113(13):2895\u2013901. This article presents the most comprehensive prognostic criteria for myelofibrosis ever published, based on high-quality analysis of over 1,000 patients.","journal-title":"Blood"},{"issue":"1","key":"68_CR5","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","volume":"109","author":"RA Mesa","year":"2007","unstructured":"Mesa RA, Niblack J, Wadleigh M, et al.: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer 2007, 109(1):68\u201376.","journal-title":"Cancer"},{"issue":"6","key":"68_CR6","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","volume":"109","author":"R Landolfi","year":"2007","unstructured":"Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al.: Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007, 109(6):2446\u201352.","journal-title":"Blood"},{"issue":"2","key":"68_CR7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","volume":"350","author":"R Landolfi","year":"2004","unstructured":"Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al.: Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004 Jan 8;350(2):114\u201324.","journal-title":"N Engl J Med"},{"issue":"5","key":"68_CR8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.blre.2005.01.001","volume":"19","author":"G Finazzi","year":"2005","unstructured":"Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 2005 Sep;19(5):243\u201352.","journal-title":"Blood Rev"},{"issue":"9","key":"68_CR9","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","volume":"21","author":"AM Vannucchi","year":"2007","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, et al.: Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia 2007 Sep;21(9):1952\u20139.","journal-title":"Leukemia"},{"issue":"1","key":"68_CR10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","volume":"353","author":"CN Harrison","year":"2005","unstructured":"Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al.: Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005 Jul 7;353(1):33\u201345.","journal-title":"N Engl J Med"},{"issue":"8","key":"68_CR11","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2008-03-143537","volume":"112","author":"JJ Kiladjian","year":"2008","unstructured":"\u2022 Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al.: Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008 Oct 15;112(8):3065\u201372. This is the first report of molecular remission in patients with PV with the use of interferon.","journal-title":"Blood"},{"key":"68_CR12","doi-asserted-by":"crossref","unstructured":"Quintas-Cardama A, Kantarjian HM, Garcia-Manero G, Cortes J, Richie MA, Borthakur G, et al.: Pegylated Interferon-ALFA-2A (PEG-IFN-\u03b1-2A; PEGASYS) Therapy Renders High Clinical and Molecular Response Rates in Patients with Essential Thrombocythemia (ET) and Polycythemia VERA (PV) [abstract]. ASH Annual Meeting Abstracts 2008, 112(11):658.","DOI":"10.1182\/blood.V112.11.658.658"},{"issue":"22","key":"68_CR13","doi-asserted-by":"crossref","first-page":"5394","DOI":"10.1182\/blood-2009-02-195974","volume":"113","author":"RA Mesa","year":"2009","unstructured":"Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 2009, 113(22):5394\u2013400.","journal-title":"Blood"},{"issue":"2","key":"68_CR14","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1600-0609.2009.01266.x","volume":"83","author":"J Huang","year":"2009","unstructured":"Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009 Aug;83(2):154\u20135.","journal-title":"Eur J Haematol"},{"issue":"6","key":"68_CR15","first-page":"595","volume":"85","author":"F Cervantes","year":"2000","unstructured":"Cervantes F, Hernandez-Boluda JC, Alvarez A, Nadal E, Montserrat E. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000;85(6):595\u20139.","journal-title":"Haematologica"},{"issue":"7","key":"68_CR16","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","volume":"101","author":"RA Mesa","year":"2003","unstructured":"Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, et al.: A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101(7):2534\u201341.","journal-title":"Blood"},{"issue":"7","key":"68_CR17","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","volume":"95","author":"A Tefferi","year":"2000","unstructured":"Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000 Apr 1;95(7):2226\u201333.","journal-title":"Blood"},{"issue":"2","key":"68_CR18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-2141.1998.00998.x","volume":"103","author":"MA Elliott","year":"1998","unstructured":"Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. British Journal of Haematology. 1998;103(2):505\u201311.","journal-title":"British Journal of Haematology."},{"issue":"4","key":"68_CR19","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1182\/blood-2006-02-004572","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, et al.: Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 Aug 15;108(4):1158\u201364.","journal-title":"Blood"},{"issue":"2","key":"68_CR20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2004.00370.x","volume":"74","author":"LN Faoro","year":"2005","unstructured":"Faoro LN, Tefferi A, Mesa RA. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Eur J Haematol 2005 Feb;74(2):117\u201320.","journal-title":"Eur J Haematol"},{"issue":"26","key":"68_CR21","doi-asserted-by":"crossref","first-page":"5264","DOI":"10.1182\/blood-2009-07-234880","volume":"114","author":"N Kroger","year":"2009","unstructured":"\u2022 Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H, et al.: Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009 Dec 17;114(26):5264\u201370. This is the most comprehensive prospective trial of allogeneic stem cell transplantation in myelofibrosis.","journal-title":"Blood"},{"issue":"12","key":"68_CR22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"\u2022 Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al.: Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med 2010, 363(12):1117\u201327. This is the first major report of the efficacy of a JAK2 inhibitor in patients with myelofibrosis.","journal-title":"N Engl J Med"},{"issue":"11","key":"68_CR23","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1182\/blood.V112.11.1760.1760","volume":"112","author":"RA Mesa","year":"2008","unstructured":"Mesa RA, Verstovsek S, Kantarjian HM, Pardanani AD, Friedman S, Newton R, et al.: INCB018424, a Selective JAK1\/2 Inhibitor, Significantly Improves the Compromised Nutritional Status and Frank Cachexia in Patients with Myelofibrosis (MF). Blood 2008 November 16, 2008;112(11):1760\u2013.","journal-title":"Blood"},{"issue":"22","key":"68_CR24","doi-asserted-by":"crossref","first-page":"a3917","DOI":"10.1182\/blood.V114.22.3917.3917","volume":"114","author":"RA Mesa","year":"2009","unstructured":"Mesa RA, Kantarjian H, Tefferi A, et al.: Validation of the Serial Use of the Myelofibrosis Symptom Assessment Form (MF-SAF) for Measuring Symptomatic Improvement: Performance in 86 Myelofibrosis Patients On INCB018424 Clinical Trial [abstract]. Blood 2009, 114(22):a3917.","journal-title":"Blood"},{"issue":"22","key":"68_CR25","doi-asserted-by":"crossref","first-page":"a755","DOI":"10.1182\/blood.V114.22.755.755","volume":"114","author":"AD Pardanani","year":"2009","unstructured":"Pardanani AD, Jason R Gotlib M, MS, Catriona Jamieson M, PhD, Jorge Cortes M, Moshe Talpaz M, Richard Stone M, et al.: A Phase I Evaluation of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis: Clinical Response Is Accompanied by Significant Reduction in JAK2V617F Allele Burden [abstract]. Blood 2009, 114(22):a755.","journal-title":"Blood"},{"issue":"22","key":"68_CR26","doi-asserted-by":"crossref","first-page":"a3905","DOI":"10.1182\/blood.V114.22.3905.3905","volume":"114","author":"S Verstovsek","year":"2009","unstructured":"Verstovsek S, Odenike O, Scott B, et al.: Phase I Dose-Escalation Trial of SB1518, a Novel JAK2\/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia\/Polycythemia Vera Myelofibrosis [abstract]. Blood 2009;114(22):a3905.","journal-title":"Blood"},{"issue":"22","key":"68_CR27","doi-asserted-by":"crossref","first-page":"a754","DOI":"10.1182\/blood.V114.22.754.754","volume":"114","author":"E Hexner","year":"2009","unstructured":"Hexner E, Goldberg JD, Prchal JT, et al.: A Multicenter, Open Label Phase I\/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC) [abstract]. Blood 2009, 114(22):a754.","journal-title":"Blood"},{"issue":"2","key":"68_CR28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.21598","volume":"85","author":"RA Mesa","year":"2010","unstructured":"Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, et al.: Phase1\/-2 study of pomalidomide in myelofibrosis. Am J Hematol 2010, 85(2):129-30.","journal-title":"Am J Hematol"},{"issue":"22","key":"68_CR29","doi-asserted-by":"crossref","first-page":"a308","DOI":"10.1182\/blood.V114.22.308.308","volume":"114","author":"J Mascarenhas","year":"2009","unstructured":"Mascarenhas J, Wang X, Rodriguez A, et al.: A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia\/Essential Thrombocythemia Myelofibrosis (Post-PV\/ET MF) [abstract]. Blood 2009;114(22):a308.","journal-title":"Blood"},{"issue":"22","key":"68_CR30","doi-asserted-by":"crossref","first-page":"a307","DOI":"10.1182\/blood.V114.22.307.307","volume":"114","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Gattoni E, et al.: RAD001, an inhibitor of mTOR, shows clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (PPV\/PET MF) [abstract]. Blood 2009, 114(22):a307.","journal-title":"Blood"},{"issue":"22","key":"68_CR31","doi-asserted-by":"crossref","first-page":"a311","DOI":"10.1182\/blood.V114.22.311.311","volume":"114","author":"S Verstovsek","year":"2009","unstructured":"Verstovsek S, Passamonti F, Rambaldi A, et al.: A phase 2 study of INCB018424, an oral, selective JAK1\/JAK2 inhibitor, in patients with advanced polycythemia vera (PV) and essential thrombocythemia (ET) refractory to hydroxyurea [abstract]. Blood 2009, 114(22):a311. First report of a JAK2 inhibitor in patients with ET and PV.","journal-title":"Blood"},{"issue":"22","key":"68_CR32","doi-asserted-by":"crossref","first-page":"a753","DOI":"10.1182\/blood.V114.22.753.753","volume":"114","author":"AR Moliterno","year":"2009","unstructured":"Moliterno AR, Hexner E, Roboz GJ, et al.: An open-label study of CEP-701 in patients with JAK2 V617F-positive PV and ET: update of 39 enrolled patients [abstract]. Blood 2009, 114(22):a753.","journal-title":"Blood"},{"issue":"32","key":"68_CR33","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1200\/JCO.2009.23.6075","volume":"27","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al.: Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009, 27(32):5418\u201324.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0068-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-010-0068-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0068-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T07:11:21Z","timestamp":1711955481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-010-0068-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["68"],"URL":"https:\/\/doi.org\/10.1007\/s11899-010-0068-4","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,16]]}}}